Table 1.
Characteristics of included microarray datasets.
| GEO accession | Contributors (submission date) | RA diagnosis criteria | Patient included criteria | Infliximab infusion | Efficacy evaluation (date) | Response categories |
|---|---|---|---|---|---|---|
| GSE3592 | Lequerre et al. (2005) | ACR (1987) | MTX treatment; DAS28=5.1; resistance to at least one DMARD (MTX included) | 3 mg/kg at weeks 0, 2, 6, and every 8th week thereafter | EULAR criteria (at week 14) | Good; moderate (categorized as non-respond); none |
| GSE8350 | Sekiguchi et al. (2007) | ACR (1987) | At least 18 yrs of age; an ACR functional class of I–III; receiving MTX ≥6 mg/week for a minimum of 3 months and a stable dose for at least 6 weeks at the time of study enrolment | 3 mg/kg at weeks 0, 2, 6, and every other 8 weeks thereafter | ACR criteria (at week 22) | Respond (ACR50%); non-respond |
| GSE12051 | Julia et al. (2008) | ACR (1987) | Active disease (DAS28 >3.2); naive to anti-TNF alpha treatment; receiving concomitant MTX treatment of ≤20 mg/wk or maximum tolerable; concomitant therapy with prednisolone (GC, dose ≤10 mg/day or equivalent) and NSAID; having stable MTX, GC and NSAID doses during the previous 4 weeks to the inclusion in the study; having discontinued previous DMARDs at least 4 weeks prior to the inclusion | At weeks 0, 2 and 14 | EULAR criteria (at week 14) | Good; moderate (categorized as respond); none |
| GSE42296 | Mesko et al. (2012) | EULAR/ACR (2010) | Age between 20 and 60 years; failure to respond to at least two DMARDs; active disease (DAS28 >3.2); anti-TNFα therapy-naive patients or previous anti-TNFα use at least 3 months prior to blood sampling | At weeks 0 and 2 | ACR criteria (at week 6 or 14) | Respond (ACR0% or ACR20%); non-respond (ACR50% or ACR70%) |
| GSE58795 | MacIsaac et al. (2014) | ACR (1987) | At least 6 tender and 6 swollen joints, CRP ≥1.0 mg/L; on a stable dose of MTX; naive to anti-TNF biologics; RAMRIS synovitis score ≥1 in the radio-carpal or intercarpal joints of one hand | 3 mg/kg at weeks 0, 2, 6 and 14 | EULAR criteria (at week 14) | Good; moderate; none |
| GSE20690 | Tanino et al. (2010) | NA | Resistant to standard MTX treatment | At week 0, and NA | Serum CRP level (at week 14) | No inflammation (CRP ≤0.3 mg/dl); residual inflammation |
| GSE33377 | Toonen et al. (2011) | ACR (1987) | First course of a TNF-blocking agent; DAS28 >3.2; previous failure on at least two DMARDs (MTX included) | At week 0, and NA | EULAR criteria (at week 14) | Good; moderate (excluded); none |
| GSE78068 | Nakamura et al. (2016) | ACR (1987) or EULAR/ACR (2010) | Responded inadequately to MTX (≥6 mg/week) | At week 0, and NA | CDAI (at month 6) | Achieving remission (CDAI ≤2.8); not achieving remission |
GEO – Gene Expression Omnibus; RA – rheumatoid arthritis; ACR – American College of Rheumatology; MTX – methotrexate; DAS28 – disease activity score 28; EULAR – European League Against Rheumatism; TNF – tumor necrosis factor; GC – glucocorticoid; NSAID – non-steroidal anti-inflammatory drugs; DMARD – disease-modifying anti-rheumatic drugs; RAMRIS – RA MRI Score; CRP – C-reactive protein; CDAI – clinical disease activity index; NA – not available.